-- Vir Biotechnology (VIR) 週一宣布，其一項評估 VIR-5500 在轉移性前列腺癌中的安全性、藥物動力學和療效的 1 期臨床試驗已啟動，並在三個擴展隊列中的一個隊列中完成了首例患者給藥。 該公司表示，針對晚期轉移性去勢抵抗性前列腺癌的單藥治療擴展隊列是第一個開始招募患者的隊列。 Vir 表示，預計將在未來幾個月內啟動劑量擴展隊列的首例患者給藥，以評估 VIR-5500 與雄激素受體通路抑製劑聯合用於早期轉移性去勢抵抗性前列腺癌和轉移性激素敏感性前列腺癌的療效。 該公司表示，預計 2027 年啟動關鍵性第 3 期臨床試驗。 Vir Biotechnology 的股價在周一的交易中下跌了 1%。
Price: $9.40, Change: $-0.10, Percent Change: -1.05%
Atlas Arteria (ASX:ALX) has received an unsolicited off-market takeover proposal from IFM to acquire all remaining securities it does not already own at AU$4.75 per share in cash, a roughly 10% premium to the company's last closing price, according to a Monday filing with the Australian bourse.IFM has indicated that the offer price may increase to AU$5.10 per share if it obtains at least a 45% relevant interest before the offer closes, subject to certain "best and final" conditions, per the filing.The offer is subject to several conditions, including required third-party consents and approvals, which may or may not be met, the filing said.The company's board has established an independent board committee to assess the proposal, and shareholders are advised to take no action, the filing added.The company's securities will be temporarily suspended from trading on the Australian Securities Exchange.
Kweichow Moutai (SHA:600519) posted a 1.47% year-over-year increase in attributable net profit in the first quarter of 2026 to 27.2 billion yuan from 26.8 billion yuan, according to a Shanghai Stock Exchange filing over the weekend.Earnings per share edged up to 21.76 yuan from 21.38 yuan.Revenue jumped 6.5% to 53.9 billion yuan from 50.6 billion yuan.
PLS Group (ASX:PLS) delivered a "strong" production quarter relative to Jefferies and market forecasts, with resilient lithium pricing through the current calendar year supporting a positive outlook, said Jefferies in a Friday note.The company on Friday reported March quarter production of 232,400 tonnes and revenue of AU$567 million compared to 125,000 tonnes and revenue of AU$150 million a year ago.The investment firm added that PLS maintains elastic production capability and a clearly defined growth pipeline.The company's "soft" third quarter sales will be unwound into the fourth quarter's resilient price environment and maintain a constructive long-term view, supported by supply demand/dynamics and operational fundamentals, the note added.Jefferies kept a buy rating on PLS and raised its price target to AU$6.70 from AU$6.The company's shares rose 1% in recent Monday trade.